fda glp 1 compounding New project announcement: HHS‑OIG is taking a closer look at FDA's oversight of compounded GLP‑1 drugs. Although shortages ended in 2025, some facilities may still be producing these drugs at scale. Our GLP-1 Drugs: Brand Companies Push
Description
GLP-1 Microdosing Options Lower, targeted doses clinician guided

But ultimately, you want to be thinner AND healthy

6 For plan sponsors, the arrival of oral options means usage could grow, reinforcing the need for comprehensive utilization-management strategies

One year of sitagliptin treatment protects against islet amyloid-associated beta-cell loss and does not induce pancreatitis or pancreatic neoplasia in mice

doi: 10.1210/jc.2002-021545
